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ABSTRACT 
 
Background: Clinical equipoise regarding preventative treatments for psychosis has encouraged the 
development and evaluation of psychosocial treatments, such as cognitive behavioural therapy 
(CBT).  
 
Method: A systematic review and meta-analysis was conducted, examining the evidence for the 
effectiveness of CBT-informed treatment for preventing psychosis in people who are not taking 
antipsychotic medication, when compared to usual or non-specific control treatment. Included 
studies had to meet basic quality criteria, such as concealed and random allocation to treatment 
groups. 
 
Results: Our search produced 1940 titles, out of which we found 7 completed trials (6 published). 
The relative risk (RR) of developing psychosis was reduced by over 50% for those receiving CBT at 
every time-point (RR at 6 months 0.47 [0.27, 0.82], p=0.008 [fixed-effects only; 6 RCTs, N=800]; RR at 
12 months 0.45 [0.28, 0.73], p=0.001 [6 RCTs, N=800]; RR at 18-24 months 0.41 [0.23, 0.72], p=0.002 
[4 RCTs, N=452). Heterogeneity was low in every analysis and the results were largely robust to the 
risk of an unpublished 12-month study having unfavourable results. CBT was also associated with 
reduced subthreshold symptoms at 12 months, but not at 6 or 18-24 months. No effects on 
functioning, symptom-related distress or quality of life were observed. CBT was not associated with 
increased rates of clinical depression or social anxiety (2 studies). 
 
Conclusions: CBT-informed treatment is associated with a reduced risk of transition to psychosis at 
6, 12 and 18-24 months, and reduced symptoms at 12 months. Methodological limitations and 
recommendations for trial reporting are discussed. 
 
Key words: Cognitive behavior therapy, at-risk mental state, prodromal psychosis, subthreshold 
symptoms. 
 
Review Registration Prospero International Prospective Register of Systematic Reviews. Protocol 
No: CRD42012002260  
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INTRODUCTION 
 
One of the most important advances in mental healthcare over the last 20 years has been the 
development of reliable methods for identifying those who are at greatly increased risk of 
developing psychosis (Chuma & Mahadun, 2011, Fusar-Poli et al., 2012a, Yung et al., 1996b). The 
success of this approach has prompted calls for the inclusion of concepts such as ‘prodromal 
psychosis’, ‘psychosis-risk syndrome’ and ‘attenuated psychosis syndrome’ in the upcoming revision 
of the American Psychiatric Association’s Diagnostic and Statistical Manual (Carpenter, 2009, 
Carpenter & van Os, 2011, Woods et al., 2010). This has sparked much controversy and debate 
(Corcoran et al., 2010, Yung et al., 2010), and it seems such proposals have now been set aside. One 
objection was that inclusion will lead to many young people being unnecessarily treated with 
antipsychotic drugs (Bentall & Morrison, 2002, Fusar-Poli & Yung, 2012, Morrison et al., 2010) – 
drugs which may be associated with a range of adverse effects, including weight-gain (McGlashan et 
al., 2006), diabetes (Mitchell et al., 2012), reduced cognitive functioning (Bowie et al., 2012, Faber et 
al., 2011) and reductions in brain tissue (Ho et al., 2011, Moncrieff & Leo, 2010, Radua et al., 2012, 
Tost et al., 2010). Although off-label prescription of antipsychotics is now not uncommon (Broome et 
al., 2005, Fusar-Poli et al., 2012b, Nieman et al., 2009), and although they lead to moderate 
improvements in symptoms for people with established psychosis (Leucht et al., 2009), whether 
they are beneficial, acceptable or harmful to young people at risk of developing psychosis remains 
unclear (Bechdolf et al., 2011, Marshall & Rathbone, 2011, McGlashan et al., 2006, McGorry et al., 
2002). It was in this context that the highly favourable results of a recent trial of omega-3 fatty acids 
(fish oils), an inexpensive treatment with no known major adverse effects, were welcomed 
(Amminger et al., 2010).  
 
Clinical equipoise regarding preventative treatments for psychosis has encouraged the development 
and evaluation of non-pharmacological psychosocial treatments, such as cognitive behavioural 
therapy (CBT) (French & Morrison, 2004, French et al., 2003) and family-focused interventions 
(O'Brien et al., 2007, Schlosser et al., 2011). Although a recent Cochrane review found no clear 
evidence of efficacy for CBT (Marshall & Rathbone, 2011) several important and relevant studies 
have been published since. If such interventions are effective in preventing or delaying psychosis, 
then this would have important implications for clinicians and policy-makers (McGorry et al., 2006).   
 
The aim of this study was to systematically review and meta-analyse the evidence for the 
effectiveness of CBT-informed care for preventing psychosis in people who are at risk but are not 
taking prophylactic antipsychotic medication, when compared to usual or non-specific control 
treatment. Meta-analysis can provide greater statistical power over individual studies, particularly 
when study heterogeneity is low. They also provide additional information concerning effect size 
precision and heterogeneity that are valuable in clarifying the nature of effects and lend themselves 
to a more comprehensive and unbiased summary of the literature than that usually attained through 
informal review. 
 
Our primary hypothesis was that CBT-informed interventions would be associated with a 
significantly reduced rate of transition to psychosis. Secondary hypotheses were that CBT-informed 
interventions would be associated with improved overall symptoms, functioning and quality of life. 
We also examined adverse effects and acceptability, the latter indexed by the numbers leaving early 
for any reason. 
 
METHODS  
 
Search 
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The Cochrane Group Trials Register (CENTRAL), PubMed, EMBASE, Medline, references of two recent 
reviews, including a systematic Cochrane review (Marshall & Rathbone, 2011, Preti & Cella, 2010), 
the online clinical trials registers of the US government (clinicaltrials.gov), European Union 
(clinicaltrialsregister.eu), World Health Organisation (apps.who.int/trialsearch) and Current 
Controlled Trials Ltd (controlled-trials.com) were searched in April 2012. The CENTRAL and PubMed 
searches were limited to the years 2008-2012, given the recent Cochrane review completed their 
last search in 2009. All years up to April 2012 were searched in EMBASE, Medline and the clinical 
trial registries. Most of the search terms used in a recent systematic review of transition outcomes in 
the at-risk group were also used here, as they seemed suitably broad (Fusar-Poli et al., 2012a). These 
were ‘psychosis risk, ultra high risk, prodromal psychosis, psychosis transition… and psychosis onset’. 
Other terms searched for were ‘psychosis prevention’ and ‘at-risk mental state’. The initial search 
was limited to the abstract, title and keywords (see PRISMA diagram, Figure 1). To ensure the work 
was up-to-date as possible, we searched for published reports of any initially unpublished trials on a 
weekly basis from April 2012 until the manuscript was accepted for publication. 
 
Studies were included only if participants at high risk of developing psychosis were randomly 
allocated to receive various interventions, one of which had to include CBT but not pharmaceutical 
treatment, and one of which had to be treatment as usual or a non-specific control treatment (i.e., 
supportive therapy, monitoring, case management). Included studies had to meet basic quality 
criteria, such as concealed and random allocation to treatment groups.  
 
Pre-registration of review protocol 
 
The review protocol was registered in advance with PROSPERO (International Prospective Register of 
Systematic Reviews) (Hutton, 2012).   
 
Data extraction and outcomes 
 
The primary outcome was transition to psychosis, as defined in each study. Secondary outcomes 
were reduction in overall symptoms (or when not reported, positive symptoms) and improvements 
in functioning (preferably Global Assessment of Functioning scores) and quality of life.   
 
A strict intention-to-treat (ITT) analysis for dichotomous data was employed, using the total 
numbers randomised to each group as the denominator in each case. Those leaving early or 
unaccounted for were assumed to have had the unchanged outcome. Examination of the impact of 
changing this assumption was intended, but only if data-reporting would allow it. For secondary 
continuous outcomes, summary data based on a mixed-model repeated measures imputation 
method were used when available; if not available, it was expected the analysis would be restricted 
to analysing data incorporating last observation carried forward assumptions. Following Leucht et 
al., we extracted and analysed mean change scores when reported, and endpoint scores otherwise 
(Leucht et al., 2009).  
 
To reduce the impact of attrition bias, study data was only included if this incorporated end-point 
scores from 50% or more of those who were randomised, excluding the analysis of leaving the study 
early. We contacted study authors to request missing or unpublished data. All extractions were 
carried out by the first author, and independently confirmed by the second. Any discrepancies were 
resolved by discussion. 
 
Meta-analytic calculations 
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For binary data, the relative risk (RR) of the unfavourable outcome together with 95% confidence 
intervals was calculated. The absolute risk difference (RD) and numbers needed to treat (NNT) were 
calculated only if the RR was significant. The NNT was calculated in two ways; (1) as the inverse of 
the RD, as per Leucht et al (Leucht et al., 2009) and (2) as the inverse of the product of the relative 
risk reduction (RRR) and an ‘assumed control risk’ (ACR), as per Higgins et al (Higgins et al., 2011b). 
Inclusion of the latter was a post-hoc decision, but one which acknowledges that “Risk differences 
are least likely to be consistent across baseline event rates; thus, they are rarely appropriate for 
computing numbers needed to treat in systematic reviews.”(Higgins et al., 2011b). ACRs were 
derived from Fusar-Poli et al (Fusar-Poli et al., 2012a).  
 
Continuous data from different outcome measures were combined to allow calculation of the 
standardised mean difference (SMD) (Higgins et al., 2011b). This and 95% confidence intervals (CI) 
were calculated using Revman software, which uses the Hedges’ g adjustment for small sample bias. 
Statistical significance was assumed if the probability of a chance result was less than 0.05, using 
two-tailed hypotheses throughout. The magnitude of effect which would be considered clinically 
significant was not pre-specified, as there is little relevant data to inform such considerations in this 
group. A random-effects analysis was used for both continuous and binary outcomes but a 
secondary analysis using fixed-effects was carried out if heterogeneity was moderate or less, as per 
the methodology of the NICE schizophrenia guidelines (NICE, 2009). Results from both are reported 
only where the estimates differ. Moderate heterogeneity was assumed if the I2 statistic was 40% 
(Higgins et al., 2011b, NICE, 2009). We also examined whether the primary outcome results were 
robust to excluding individual studies from the analysis. Calculations were performed by the first 
author, and independently replicated by the second. There were no discrepancies. 
 
Risk of bias 
 
Risk of bias was assessed with the Cochrane Collaboration Risk of Bias tool (version 5.1.0) (Higgins et 
al., 2011b). This involves categorising studies as having a low, high or unclear risk of bias in the areas 
of selection and allocation of participants, intervention concealment, attrition and reporting (Higgins 
et al., 2011a). The results of this assessment were used to inform intepretation of reported effect 
sizes and overall conclusions.   
 
RESULTS 
 
Study selection 
 
The process of selecting studies is detailed in Figure 1. The initial search produced 1940 papers and 
conference abstracts. The vast majority of these were clearly irrelevant (e.g., involved different 
clinical population such as dementia or established psychosis, or were brain imaging studies, 
antipsychotic trials or correlational studies). Overall, 48 were possibly relevant. Screening of 
abstracts reduced this to 14. The full-text publications or reports for each of these were traced. A 
further 6 were then excluded as they did meet inclusion criteria (see Figure 1). A total of 8 studies 
were relevant, 2 of which could not be included because they were ongoing (Bechdolf et al., 2011) or 
have yet to be published (Stain, 2012 – see Table 1). Trial publication details are given in Table 1.  
 
Study characteristics and treatment 
 
Trial characteristics and baseline demographics for all studies are given in Table 2.  
 
The CBT provided was based on published treatment manuals. Four trials (Addington et al., 2011, 
Morrison et al., 2012a, Morrison et al., 2004, Rietdijk et al., 2010) were based on one approach 
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(French & Morrison, 2004). The remaining two trials (Bechdolf et al., 2012, McGorry et al., 2012) 
were each based on one of two other published manuals (Bechdolf et al., 2010, Yung et al., 2004). All 
approaches involved time-limited and structured sessions, formulation, self-monitoring, 
collaboration, homework between sessions, use of cognitive and behavioural experiments and other 
strategies to address unhelpful appraisals and improve coping, a focus on patient goals and work on 
addressing a range of difficulties as prioritised by the patient.  
 
Risk of bias 
 
Selection bias refers to the risk of researchers being able to influence, or have knowledge of, 
allocation of participants to treatment (Higgins et al., 2011a). Such bias has been found to inflate 
effect size estimates by around 30-40% (Schulz et al., 1995). A particular strength of the included 
trials was that randomisation and allocation procedures were clearly described and adequate in 
most cases, meaning such bias was generally low. However, although well-described and involving 
adequate concealment, the randomisation procedure in Morrison 2004 produced significantly 
unequal sample sizes, meaning the risk of selection bias was unclear. 
 
Detection bias refers to the risk that those completing outcome assessments know who received 
which treatment (Higgins et al., 2011a). This is more of a problem when the assessments depend on 
the subjective judgement of the assessor (e.g., diagnosis), and less of a problem when they are more 
objective (e.g., death, unemployment). The risk of bias in this domain was unclear in 2 out of 6 trials 
because they did not report whether or not there were blind-breaks (Addington et al., 2011, Yung et 
al., 2011), and high in one study because they did not report attempts to use blinding (Bechdolf et 
al., 2012) and described their study as open-label in their published protocol. The other 3 studies did 
report some blind-breaks (Morrison et al., 2012a, Morrison et al., 2004, van der Gaag et al., 2012), 
however we assessed risk of bias as low for at least the assessment of transition because each trial 
introduced new blinded raters to either take over or validate the assessments, while one trial also 
validated their assessments by comparing them to an external measure with some ecological validity 
- prescription of antipsychotic medication by an independent psychiatrist (Morrison et al., 2004). 
Incidence of unblinding was also relatively low (5-22%) in two studies (Morrison et al., 2012a, van 
der Gaag et al., 2012), although precise figures were not reported for the third (Morrison et al., 
2004). 
 
Performance bias refers to the risk of participants or clinical personnel being aware of treatment 
allocation (Higgins et al., 2011a), as this may result in a change in behaviour designed to please the 
experimentor. A high risk of such bias is unavoidable in therapy trials, particularly when assessments 
rely on participant self-report, and indeed there is evidence from two included trials that at least 
some participants are able to conceal psychotic symptoms if motivated to do so (Morrison et al., 
2004, van der Gaag et al., 2012).  
 
There was a high risk of bias from selective reporting by Bechdolf 2012, in that no continuous 
symptom endpoint or change data were reported in either the main (Bechdolf et al., 2012) or a 
secondary publication (Bechdolf et al., 2007), despite this being identified a priori as a secondary 
outcome (see Table 1 for details of online trial protocol). The first author has advised there were no 
group differences with respect to symptoms, but these analyses were not reported in the main 
publication because peer-reviewers argued the figures would be distorted by the premature exit of 
those who developed psychosis.  
  
A number of outcomes from Morrison 2012 (Morrison et al., 2012a) (quality of life at all assessment 
points, and all outcomes at 24-months) were at high risk of attrition bias due to large amounts of 
missing data (>50%) over and above planned drop-out (Xia et al., 2009). This was also true for all 36-
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month outcomes from Morrison 2004 (Morrison et al., 2007, Morrison et al., 2004). In the other 
studies, attrition bias was either low for the primary analysis of transition rates, or unclear (McGorry 
et al., 2012). Risk of attrition bias inevitably increases as drop-out increases, which in turn is 
normally a function of trial duration. Thus the longer-term outcomes are more suspect in this 
domain than shorter-term outcomes. 
 
Outcomes 
 
Primary outcome (see Figures 2-4) 
 
Transition at 6-months: All 6 trials contributed to this outcome, providing data from 800 
participants. The difference in transition rates observed in the random-effects analysis (RR 0.52 
[0.27, 1.02], p=0.06) just failed to meet the criterion for statistical significance, meaning the odds of 
such a difference arising by chance alone were 1:17 instead of the requisite 1:20. Results achieved 
statistical significance (p=0.03) if we excluded equivocal data from (Yung et al., 2011).  
 
Since heterogeneity was low (13%), a fixed-effects analysis was also conducted, as per our protocol. 
In this analysis the effect size was comparable if not slightly larger (RR 0.47 [0.27, 0.82]) but highly 
statistically significant (p=0.008), meaning the odds of the observed differences arising by chance 
alone were 1:125. These odds fell to 1:17 (p=0.06) if we removed CBT favourable results from the 
large van der Gaag et al trial (van der Gaag et al., 2012).  
 
Based on an observed absolute risk reduction of -0.05 [-0.08, -0.01], the number needed to treat for 
all 6 studies combined was 20 (13, 100). However the control group transition rate of 9% (4% in CBT; 
6% overall) was lower than other meta-analytical estimates, where 18% were found to make 
transition over 6 months (Fusar-Poli et al., 2012a). The NNT estimate derived from the product of 
the Fusar-Poli et al transition rate and our observed fixed effect RRR was considerably smaller at 10 
(8, 31).  
 
The control group transition rate increased to 12% (5% in CBT; 9% overall) if we excluded both a 
study of early prodromal psychosis (i.e., where fewer would be expected to develop psychosis) 
(Bechdolf et al., 2012), and a study where 29 potential participants were excluded because they 
developed or disclosed established psychosis between baseline assessments, before they were 
randomised (Morrison et al., 2012a). 
 
Sensitivity analyses: The magnitude and precision of the effect favouring CBT was reduced if we 
excluded the Bechdolf 2012 study (random effects: RR 0.58 [0.31, 1.07], p=0.08; fixed effects: RR 
0.55 [0.31, 0.99], p=0.05, RD-NNT 25 [13, ∞], ACR-NNT 12 [8, 556]), which differed from the other 
trials in respect of non-masked assessments, additional psychosocial interventions received by the 
CBT group (cognitive remediation, family psychoeducation) and population studied (early 
prodromal). Since this study was described as CBT in both the trial protocol and in a previous 
publication (Bechdolf et al., 2007), and since they reported the numbers developing a first episode 
of psychosis, we deemed inclusion to be valid. The effect size was also slightly smaller and less 
precise if we assumed the 7 participants in 2 RCTs (Morrison et al., 2004, van der Gaag et al., 2012) 
assessed as having concealed their pre-randomisation transition to psychosis (e.g., as evidenced by 
past antipsychotic use or self-report) were in fact new transitions (random effects: RR 0.64 [0.37, 
1.11], p=0.11; fixed effects: RR 0.56 [0.34, 0.94], p=0.03, RD-NNT 25 [13, 100], ACR-NNT 13 [8, 93]).  
 
Transition at 12-months: All 6 trials also contributed data to this outcome. A random-effects analysis 
found CBT was associated with a significantly reduced risk of transition (RR 0.45 [0.28, 0.73], 
p=0.001, RD -0.09 [-0.14, -0.04]), with a numbers needed to treat of between 11 (7, 25), using the 
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inverse of the observed RD, and 8 (6, 17) using the observed RRR and an assumed control risk of 22% 
(Fusar-Poli et al., 2012a). No heterogeneity was observed, however the fixed-effects analysis 
produced a slightly better relative risk estimate (RR 0.40 [0.25, 0.64], p=0.0001) and a slightly 
reduced estimate of the absolute risk reduction (RD -0.08 [-0.12, -0.04]). The results were robust to a 
leave one-out analysis, suggesting they were not driven by one trial alone. 
 
Overall, just over 13% of the control-group participants included in this analysis developed psychosis 
(5% in the CBT group; 9% overall), which is clearly lower than the 22% reported elsewhere (Fusar-
Poli et al., 2012a). Removing data from the 2 trials where baseline transition risk may have been 
reduced by trial design issues (Bechdolf et al., 2012, Morrison et al., 2012a) resulted in a comparable 
control group transition rate of 18% (7% in CBT; 12% overall). The pooled data from the remaining 4 
trials remained favourable to CBT, if not slightly more so.  
 
Sensitivity analyses: The magnitude and precision of effect favouring CBT was slightly reduced if we 
excluded the Bechdolf (2011) study, according to both random and fixed effects analyses (RR 0.48 
[0.30, 0.79], p=0.001, RD -0.07 [-0.13, -0.02], RD-NNT 14 [8, 50], ACR-NNT 9 [6, 22]). Reclassifying 7 
pre-randomisation transitions in 2 RCTs as post-randomisation transitions was also associated with a 
slight reduction in effect size magnitude in both the random (RR 0.53 [0.34, 0.82], p=0.005, RD -0.08 
[-0.13, -0.03], RD-NNT 13 [8, 33], ACR-NNT 10 [7, 25]) and fixed effects analyses (RR 0.47 [0.30, 0.72], 
p=0.0005, RD -0.08 [-0.12, -0.03], RD NNT 13 [8, 33], ACR NNT 9 [6, 16]).  
 
Transition at 18-24 months: Four trials provided usable data from 452 participants. A random-effects 
analysis found CBT was associated with a reduced likelihood of transition (RR 0.41 [0.23, 0.72], 
p=0.002, RD -0.12 [-0.18, -0.06]). The NNT was 8 (6, 14) when derived from the observed RD, and 6 
(5, 11) when derived from the observed RRR and an assumed control risk of 27-29% (Fusar-Poli et 
al., 2012a). Heterogeneity remained absent (0%), but the fixed effect analysis produced slightly more 
favourable results (RR 0.36 [0.21, 0.63], p= 0.0004, RD -0.12 [-0.18, -0.06]), although the NNT 
estimates were unaffected. Although Morrison 2012 reported equivocal 24-month data, over 50% of 
this was missing even after accounting for planned drop-out, therefore this was not included in the 
analysis. The results were also robust to a leave one-out analysis.  
 
Approximately 18% of control-group participants in these 4 trials converted to psychosis by 18-24 
months (6% in CBT; 12% overall), whereas Fusar-Poli and colleagues reported rates of 27% (18 
months) and 29% (24 months). Excluding the Bechdolf (2011) study was associated with marginally 
increased transition rates in the control group (19%), the CBT group (8%) and overall (14%). 
 
Sensitivity analyses 
 
Excluding the Bechdolf study was also associated with a marginal reduction in magnitude of effect 
favouring CBT (random-effects: RR 0.46 [0.28, 0.75], p=0.01, RD -0.11 [-0.17, -0.05]; fixed-effects: 
0.44 [0.27, 0.72], p=0.007, RD -0.11 [-0.17, -0.05]) with NNTs ranging from 6 (5, 12; based on RRR of 
0.56 and ACR of 29%) to 9 (6, 20; based on RD of -0.11). Re-classifying 5 pre-randomisation 
transitions in van der Gaag et al (2012) as post-randomisation transitions had a slight effect on the 
fixed effect analysis only (RR 0.42 [0.27, 0.64], p=0.0008, RD -0.11 [-0.16, -0.06]), with NNT estimates 
ranging from 6 (5, 10; based on RRR of 0.58 and ACR of 29%) to 9 (6, 17; based on RD of -0.11).   
 
Eighteen-month data from McGorry et al (2012) suffered from 47% missing data (McGorry, Yuen and 
Yung, personal communication) while transition at this time-point was defined pragmatically as 
receipt of (a) help from a State psychiatric hospital and (b) a diagnosis of psychotic illness (McGorry, 
Yuen and Yung, personal communication), as inferred from medical records (McGorry et al., 2012). 
Excluding this potentially less reliable data was associated with an increase in the magnitude of the 
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CBT-favourable effect size in the random-effects analysis (RR 0.30 [0.12, 0.72], p=0.02, RD -0.13 [-
0.18, -0.07]), with the most favourable NNT estimate now being 5 (4, 12; based on RRR of 0.70 and 
ACR of 29%) and the least favourable now being 8 (6, 14; based on fixed-effects RD of -0.12). 
 
Although these results are promising, the reporting of transition rates and numbers leaving early did 
not allow the impact of changing assumptions about the outcome of those who left early to be easily 
assessed. For example, it was often not clear from the study reports whether the numbers lost to 
follow-up or numbers failing to complete assessments included those who made transition before 
that particular assessment point. Thus the figures reported above may not be robust to changing 
assumptions about the outcome of those leaving early. 
 
Test of robustness of findings to unpublished study: One obvious concern is that the completed 12-
month study remains unpublished because of disappointing findings. In order to test how the overall 
results would be affected by this risk, we entered either equivocal or even highly unfavourable data 
for this trial into the meta-analysis, using information in the published protocol. In each case we 
made several reasonable but conservative assumptons, which were: (1) the researchers recruited to 
target (N=78); (2) each group had an N of 39; (3) the transition rate in the control group was the 
same as the combined control-arm transition rate of all the other studies (i.e., 6 months: 9%; 12 
months: 13%). 
 
These tests suggested that, at 6 months, the overall RR for the favourable fixed effect analysis would 
be slightly smaller if we assume an equivocal result (RR 0.52 [0.31, 0.87], p=0.01), meaning the 
relative risk of transition would be reduced by 48% rather than 53%. Although the absolute risk 
reduction would only be slightly smaller (RD -0.04 [-0.08, -0.01]) the RD-derived NNT would increase 
from 20 to 25 (13, 100). The ACR-derived NNT, based on an 18% transition rate (Fusar-Poli et al., 
2012a) and an RRR of 0.48, would  increase to 12 (8, 51). If, compared to the control group, twice as 
many people in the CBT-group developed psychosis by 6 months then the pooled effect size would 
be smaller and of borderline statistical significance (RR 0.62 [0.38, 1.00], p=0.05, RD -0.03 [-0.07, -
0.00]).  
 
At 12 months, the overall RR would be slightly smaller for the favourable random-effects analysis if 
we assume an equivocal result (RR 0.51 [0.32, 0.80], p=0.004; RD -0.08 [-0.13, -0.03]), leading to an 
RD-derived NNT of 13 (8, 33) and an ACR-derived NNT of 10 (7, 23; based on 22% transition rate and 
an RRR of 0.49). If we assume twice as many people receiving CBT made transition than those 
receiving the control treatment, then the magnitude of the effect size estimate would remain largely 
unaffected (RR 0.54 [0.27, 1.06], RD -0.07 [-0.14, -0.01]), but statistical significance would decline to 
trend level (p=0.07). Of course this would not render CBT ineffective; rather it would suggest a need 
to investigate what was causing the now considerable 49% heterogeneity (NICE, 2009). 
 
Importantly, the Stain study researchers have advised that (a) there were few transitions in their 
study (b) that they recruited ~57 participants instead of the target 78 (Stain, personal 
communication, 2012) and (c) the reasons for non-publication do not relate to null findings.  
Unfortunately group comparison data were not provided. 
 
Secondary outcomes (Figures 5 and 6) 
 
Symptoms  
 
Data from 4 trials (Figure 5) did not suggest a difference in overall symptom severity between groups 
at 6 months (Hedges’ g -0.07 [-0.25, 0.12], p=0.48) and data from 2 trials did not suggest a difference 
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in symptom-related distress (g -0.16 [-0.53, 0.22], p=0.15), although there was notable 
heterogeneity (68%) in this analysis. 
 
At 12 months, available data from 5 trials suggested CBT was associated with a small effect on 
symptoms (Hedges’ g -0.25 [-0.46, -0.03], p=0.02). If we used endpoint instead of mean change data 
for the Yung (2011) study, then the effect was smaller and achieved statistical significance only when 
a fixed-effects analysis was used (g -0.20 [-0.39, -0.02], p=0.03). Data from 2 trials did not reveal a 
significant difference in symptom-related distress (g -0.17 [-0.39, 0.05], p=0.14). 
 
Small benefits in symptom severity at 18-24 months in the two trials reporting usable data 
(Addington et al., 2011, van der Gaag et al., 2012) did not achieve statistical significance, regardless 
of whether we used frequency (g -0.26 [-0.57, 0.04], p=0.09) or intensity data (g -0.17 [-0.47, 0.14], 
p=0.28) from van der Gaag (2012). No difference in symptom-related distress was found in the one 
trial reporting usable 18-month data (van der Gaag et al., 2012). CBT-favourable 18-24 month 
severity and distress data from Morrison 2012 suffered from >50% attrition and were therefore 
excluded. 
 
Functioning 
 
Three trials reported usable 6-month data on the Global Assessment of Functioning (GAF) scale 
(Figure 6), while one reported usable data on the Social Functioning Assessment Scale (SOFAS). No 
difference was observed (g -0.03 [-0.31, 0.25], p=0.84; negative sign = CBT worse). At 12-months, no 
difference was again observed in a combined analysis of GAF, SOFAS or Social Adjustment Scale II 
data from 5 trials (g. 0.03 [-0.21, 0.27], p=0.78). GAF results from Morrison 2004 suffered from >50% 
missing data. Two trials reported usable GAF data at 18 months, but no difference was detected (g 
0.09 [-0.21, 0.39], p=0.56). Twenty-four month GAF data from Morrison 2012 was not usable due to 
missing data.  
 
Quality of life 
 
Data from two trials did not reveal group differences in relation to quality of life at 6 months (g -0.09 
[-0.35, 0.18], p=0.52), or at 12 months (g 0.00 [-0.28, 0.28], p=0.99).  No group differences were 
observed at 18 months in the one trial reporting usable data at this time-point (g 0.11 [-0.22, 0.44], 
p=0.51) (van der Gaag et al., 2012). Morrison (2012) reported equivocal results at 6, 12 and 24 
months, but over 50% of the data was missing at each time point, and therefore was not included in 
the analysis.  
 
Adverse effects 
 
Limited data on adverse effects were available from 5 studies, most of which could not be combined 
for meta-analysis. Bechdolf (2012) reported that no participants were withdrawn for deteriorating 
mood or suicidal ideation (Bechdolf et al., 2012) while analysis of reasons for drop-out in Addington 
(2011) suggested 1 person receiving supportive therapy discontinued after 3 months due to 
subjective fears of worsening paranoia and referential thinking (Addington et al., 2011). 
 
McGorry 2012 reported adverse effects at 6 months, however data was missing from almost 50% of 
participants and 12-month data was available for only 33% of those randomised(McGorry et al., 
2012). At 6-months, no significant differences were observed between CBT plus placebo (N=44) and 
supportive therapy plus placebo (N=28) with respect to significant weight-gain (2 vs 1, for the CBT 
and control groups respectively),  fatigue (14 vs 8), depression (11 vs 5), concentration problems (7 
vs 2), orthostatic dizziness (3 vs 3), or the psychic (18 vs 11), neurologic (4 vs 2), autonomic ( 13 vs 8) 
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or ‘other’ (11 vs 6) Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Subscales (Lingjaerde 
et al., 1987) (all p>0.05).   
 
No differences in numbers with clinical levels of social anxiety (6 months: RR 0.93 [0.67, 1.30], 
p=0.67; 12 months: 1.05 [0.73, 1.51], p=0.80) or depression (6 months: RR, 0.94 [0.74, 1.19, p=0.58; 
12 months: RR 0.88 [0.67, 1.15], p=0.35) were observed in the two trials reporting this data. One 
trial reported 18-month data, and no significant differences were found (van der Gaag et al., 2012). 
Morrison 2012’s 24-month figures were uninterpretable due to missing data. 
 
Leaving the study early for any reason (Figure 7) 
 
No differences in numbers leaving early for any reason were observed at 6 months (4 RCTs, RR 1.08 
[0.82, 1.41], p=0.59), 12 months (6 RCTs, RR 0.99 [0.80, 1.23], p=0.96), 18-24 months (4 RCTs, RR 
0.95 [0.79, 1.15], p=0.62) or 36 months (1 RCT, 0.96 [0.60, 1.52], p=0.85).  
  
DISCUSSION 
 
The results of this meta-analysis are encouraging, and suggest that prevention or delay of the onset 
of psychosis is achievable with a psychosocial treatment alone. CBT was associated with a 
signficantly reduced rate of conversion to first-episode psychosis at 6, 12 and 18-24 months after 
treatment, compared with those receiving either monitoring or non-specific supportive therapy. The 
6-month estimate was somewhat less robust, perhaps because of limited statistical power to detect 
differences in a relatively low-frequency event. 
  
At every time-point, the relative risk of transition was reduced by over 50% for those receiving CBT. 
Overall between 8 and 11 need to receive CBT instead of, or in addition to, non-specific support for 
one person to avoid transition over the longer term (12 to 18-24 months). Such figures compare 
favourably to other preventative treatments in medicine. According to a recent comparison of 
psychiatric and general medical treatments, around 27 (25, 33) patients with heart disease need to 
take statins to prevent one major cardiac event, while around 16 (13, 25) need to take ACE-inhibitors 
for one to avoid death from chronic heart failure (Leucht et al., 2012).  
 
However, the NNT estimates do not just reflect treatment efficacy. They are also very much 
influenced by the positive predictive value (PPV) of the high-risk criteria. If the PPV of the criteria is 
low (i.e., few people classified as at-risk actually make transition), then the NNT will be higher 
regardless of the efficacy of a treatment. Likewise, once methods of predicting risk of transition 
improve, fewer people who are unlikely to make transition anyway will need to receive prophylactic 
treatment, and the NNT will be lower. In this context, relative risk estimates are a much better index 
of treatment-attributable benefits than are NNTs.  
 
Interestingly the rate of transition in the control conditions of 9-18% is considerably lower than the 
18-29% reported in a recent meta-analysis (Fusar-Poli et al., 2012a). Although transition rates were 
somewhat higher (12-19%) after excluding 2 studies where baseline transition risk was potentially 
diluted by trial design features, there is still a clear difference between these data-sets. This might 
suggest risk of transition can be substantially reduced by trial participation, where people have 
greater access to relatively inexpensive supportive approaches such as regular monitoring, sign-
posting and support. Although Fusar-Poli and colleagues reported a transition rate of 33% in those 
receiving standard psychiatric care and case management (Fusar-Poli et al., 2012a), perhaps the 
relatively persistent and accessible attention offered by trial researchers and therapists reduces the 
risk of crises and unmet psychosocial need? Alternatively, the low transition rate may suggest fewer 
participants in the CBT trials included here were genuinely ‘at-risk’, and that the PPV of the high-risk 
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criteria needs improving (Morrison et al., 2012a). The potential implications of this uncertainty for 
inclusion of an attenuated psychosis syndrome in DSM-V have been outlined elsewhere (Morrison et 
al., 2012a). 
 
The results from the secondary analyses are harder to interpret. Although there was some evidence 
that CBT had a small effect on symptoms at 12 months (-0.25), the differences observed at other 
time points were not statistically significant. The 12-month effects are comparable to the 
nonsignificant effect sizes of between -0.12 (-0.62, 0.38; PANSS total) and -0.26 (-0.76, 0.25; SOPS 
total) reported in a double-blind 1-year trial of olanzapine vs placebo for prodromal patients 
(McGlashan et al., 2006). However, the significant effect size for weight gain in that study was 1.18 
(0.63, 1.72), many participants left early, and the results have yet to be replicated. Although the 12-
month CBT effect size is much smaller than the large effect size of -0.88 (-1.34, -0.44; PANSS total) 
reported in a double-blind study of omega-3 fatty acids vs placebo (Amminger et al., 2010), this 
study also awaits replication.  
 
Also on the negative side, the secondary analysis suggests CBT has yet to demonstrate effectiveness 
in improving functioning in this group, at any time-point. This is an important finding, and suggests 
existing CBT packages should be modified to target functioning specifically. An approach based on a 
specific cognitive model of low functioning (Beck et al., 2013, Grant & Beck, 2009) has recently 
shown promise in chronic established psychosis (Grant et al., 2012) and could perhaps be adapted 
for the at-risk group. Other psychosocial treatments, such as family-focused interventions, may also 
have an important role to play here (O'Brien et al., 2007, Schlosser et al., 2011). Similar results were 
found for quality of life, although there was only limited data on this outcome.  
 
However one problem with the CBT trials is that there seems to be no consensus on the best way to 
analyse and report continuous outcome data. Some authors excluded data from those who made 
transition (van der Gaag et al., 2012), some made transition an exit criterion for the trial but carried 
forward the last observation of those who converted (Bechdolf et al., 2007), while some kept 
everyone in the trial and did not exclude any data from any time-points (Morrison et al., 2012a, 
Morrison et al., 2004). This latter approach seems most sensible to us, as it allows direct assessment 
of the real-world impact of CBT, minimises the use of crude imputation strategies, and helps to 
preserve the benefits of randomisation that exclusions inevitably remove (Hamer & Simpson, 2009, 
Schulz & Grimes, 2002). Of course if more in the control treatment develop psychosis and then 
receive antipsychotics, then this may mask any beneficial effects of CBT at endpoint. However 
exposure to these drugs may also be associated with more adverse effects (McGlashan et al., 2006) 
– effects which, if measured, should greatly inform the cost-benefit analysis. It should also be 
remembered that transition itself is an adverse event. If all trials retained all participants and their 
data in the analysis, then we would be able to provide young people with much more accurate 
information about what is likely to happen to them if they decide CBT is not for them.  
 
Limitations 
 
One possible concern is that the limited number of trials with usable outcome data (N=6) precludes 
the use of meta-analysis. However meta-analyses have been applied successfully to numerous other 
commonly used treatments for psychosis, many of which have a comparable number of studies and 
participants. For example, there are now more data on the long-term benefits of CBT for psychosis 
prevention than there are for the long-term benefits in established psychosis, compared to placebo, 
of drugs such as chlorpromazine (Adams et al., 2007), haloperidol (Joy et al., 2006), olanzapine, 
quetiapine and aripiprazole (Leucht et al., 2009). Historically only 3-5 short-term trials have been 
required by the US Food and Drug Administration to license a new antipsychotic [e.g., (Dubitsky et 
al., 2002)], and the median number of studies in a typical Cochrane review is, across medicine, six 
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(Mallett & Clarke, 2002). According to some experts only 2 studies are required for meta-analysis 
“because all other synthesis techniques are less transparent and/or are less likely to be valid.” 
(Valentine et al., 2010) . 
 
Sources of heterogeneity were not investigated, but this was generally low or absent. The trials were 
similar enough to combine in a meaningful way and subgroup analyses would not be informative at 
this stage. Such considerations should not be an obstacle to answering the simple question of 
whether CBT is benefical or not. The control conditions varied somewhat, in that some trials 
compared CBT-informed interventions to basic monitoring, while others used a supportive therapy 
control. Arguably the latter provide a more definitive assessment of the importance of specific CBT 
strategies, such as normalising and behavioural experiments (French & Morrison, 2004, Morrison & 
Barratt, 2010). Future meta-analyses will have greater power to conduct separate comparisons, 
looking at CBT versus usual treatment and CBT versus a control condition.  
 
The limited number of trials also means it would be uninformative at this stage to conduct tests for 
publication bias. Fail-safe N analyses are not recommended (Higgins et al., 2011b), and at least 10 
trials are thought to be sufficient to ensure adequate power for funnel-plot tests (Ioannidis & 
Trikalinos, 2007). Meta-analytical assessment of treatment efficacy should not depend on having 
adequate power for such tests. Such a rule would be remarkably conservative and preclude meta-
analyses of almost all individual treatments for psychosis as well as treatments for many other 
conditions. Publication bias has now been thoroughly investigated in meta-analyses of psychosocial 
treatments for psychosis, including meta-analyses of CBT, and this has not been found to be a major 
threat to the integrity of the main findings (Niemeyer et al., 2012). We have shown that our primary 
outcome results are reasonably robust to the (low) risk of the one unpublished completed study 
having highly unfavourable results.  
 
Recommendations for future trial design 
 
Although these are promising results, firmer conclusions about the benefits and costs of CBT-
informed treatment for this group are limited by methodological problems such as small sample 
sizes, difficulties maintaining the single-blind, selective reporting of outcomes and inconsistent 
assessment or reporting of potential adverse effects. However these issues are certainly not unique 
to these trials (Leucht et al., 2008, Miyar & Adams, 2012, Perlis et al., 2010, Schulz et al., 1995, 
Thornley & Adams, 1998) nor do they vitiate the main findings.  
 
One particular strength of the trials included here is that they suffer from relatively low rates of 
missing data, and clearly reported their randomisation and treatment allocation procedures. Most 
trials also published their trial protocol in advance of their main publication, thus reducing scope for 
bias, which is also a strength of our systematic review (Bushe, 2011). All except one (McGorry et al., 
2012) were health service or government-funded, and the researchers generally had few financial 
conflicts of interest. Inclusion criteria were also not overly restrictive, thus increasing 
generalisability.  
 
One particular limitation was the non-thorough and inconsistent assessment and reporting of 
adverse effects. Researchers should consider developing a standard protocol for assessing adverse 
effects in trials for the at-risk group. This may include reporting the number of people in each 
condition experiencing a pre-defined degree of deterioration in mood, functioning or quality of life, 
as well as serious adverse events (e.g., strong suicidal intent, suicide attempts, violence). This is 
important given preliminary evidence suggesting there may be a high prevalence of suicide risk 
factors in the at-risk population (Hutton et al., 2011, Zimbron et al., 2012). Two recent trials of CBT 
for established psychosis provide examples of good practice for reporting harms (Klingberg et al., 
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2012, Klingberg et al., 2010) and CONSORT provide a sensible set of recommendations (Ioannidis et 
al., 2004). 
  
Conclusion and clinical implications 
 
Provision of CBT was associated with a reduced risk of transition to psychosis at 6, 12 and 18-24 
months, although the 6-month benefit was less robust. The results challenge the clinical equipoise 
which has so far characterised the field.  Based on these findings, we recommend that young people 
seeking help for an at-risk mental state should now be offered a package of care which includes at 
least 6 months of structured CBT based on one of the manuals used in these trials, and delivered by 
an appropriately qualified and experienced professional. These young people should be advised that 
engaging with CBT could halve their risk of developing psychosis over an 18-24 month period, 
although they are unlikely to gain additional benefits in relation to functioning or quality of life. They 
should also be advised that the available evidence suggests CBT is unlikely to lead to increased 
depression or social anxiety, but that data on adverse effects is generally very limited. This 
recommendation should not be taken to imply that other treatments should not also be offered to 
this group, if proven effective. We are advocates of treatment choice (Morrison et al., 2012b) which, 
to be meaningful, requires several effective treatments to choose from.  
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Figure 1 PRISMA flowchart detailing study selection  
 
Number of records 
identified through 
database searching: 
1924 
    
Number of records 
identified through 
other sources: 16 
 
 
 
 
  
      
      
  
Number of irrelevant 
/ duplicate records 
excluded on basis of 
title: 1893 
   
  
 
   
      
      
  
Number of records 
screened (abstract / 
description): 48 
 
 
Number of records 
excluded: 34 
  
 
   
      
  
Number of full-text 
reports screened for 
eligibility: 14 
 
 
Number of full-text 
reports excluded: 6 
  
 
  
Duplicate report: 2 
No CBT group in trial: 2 
Participants taking 
antipsychotics: 2 
 
  
Number of studies 
included in meta-analysis: 
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Figure 2 Transition at 6-months 
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Figure 3 Transition at 12-months 
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Figure 4 Transition at 18-24 months 
 
  
24 
 
 
Figure 5 Symptoms at 6, 12 and 18-24 months 
 
(a) 6 months 
 
(b) 12 months 
 
(c) 18-24 months 
 
Model Study name Statistics for each study Sample size Hedges's g and 95% CI
Hedges's Lower Upper 
g limit limit p-Value Drug Placebo
Addington 2011 -0.263 -0.952 0.426 0.455 16 15
Morrison 2012 severity -0.356 -0.643 -0.069 0.015 95 93
Morrison 2004 -0.545 -1.073 -0.017 0.043 35 23
van der Gaag 2012 intensity 0.045 -0.273 0.362 0.783 75 76
Yung 2012 mean change -0.322 -0.912 0.267 0.284 27 18
Fixed -0.239 -0.419 -0.058 0.010 248 225
Random -0.248 -0.462 -0.033 0.024 248 225
-1.00 -0.50 0.00 0.50 1.00
CBT Control
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Figure 6 Functioning at 6, 12 and 18-24 months  
 
(a) 6 months 
 
(b) 12 months 
 
 
 
 
(c) 18-24 months 
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Figure 7 Leaving the study early (any reason) 
 
(a) 6 months 
 
(b) 12 months 
  
(c) 18-24 months 
 
 
(d) 36 months 
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Table 1 Trial details 
 
Trial Year of 
completion 
Was trial protocol 
registered in public 
domain? 
Reference(s) for 
primary 
publication(s) 
Reference for 
peer-reviewed 
pre-results 
protocol 
Included in meta-analysis 
 
 -  
Addington 2011 Yes1 (Addington et al., 
2011) 
-  
Bechdolf 2011 Yes2 (Bechdolf et al., 
2012, Bechdolf et 
al., 2007) 
-  
Morrison 2004 No (Morrison et al., 
2004) 
(Morrison et al., 
2002) 
Morrison 2012 Yes3 (Morrison et al., 
2012a) 
(Morrison et al., 
2011) 
Yung 2011 Yes4 (McGorry et al., 
2012, Yung et al., 
2011) 
(Phillips et al., 
2009) 
Van der Gaag 2011 Yes5 (van der Gaag, 
2012, van der 
Gaag et al., 2012) 
(Rietdijk et al., 
2010) 
Not included in meta-analysis 
 
  
Bechdolf Ongoing Yes6  Not complete (Bechdolf et al., 
2011) 
Stain 2012 Yes7 Not published or 
available 
-  
1 http://clinicaltrials.gov/ct2/show/study/NCT00260273  
2 http://clinicaltrials.gov/ct2/show/NCT00204087  
3 http://www.controlled-trials.com/ISRCTN56283883 
4 http://www.anzctr.org.au/trial_view.aspx?ID=322  
5 http://www.controlled-trials.com/ISRCTN21353122  
6 http://www.controlled-trials.com/isrctn/pf/02658871   
7
 http://www.anzctr.org.au/ACTRN12606000101583.aspx  
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Table 2 Trial characteristics and baseline demographics 
 
       Baseline demographics  
Trial Treatments Number 
randomise
d 
Maximum 
duration of 
treatment, 
months 
(no. 
therapy 
sessions) 
Primary 
criterion used 
to determine 
at-risk mental 
state 
Primary 
criterion used 
to determine 
transition to 
psychosis 
Number of 
centres, 
location 
(country) 
Age, 
mean 
(SD)  
Number 
female 
(%) 
Baseline 
symptom 
severity, 
measure used, 
mean score 
(SD) 
Follow-up 
data 
available 
(months 
after 
baseline) 
Included in meta-analysis 
 
 
        
Addington 
2011 
(Addington 
et al., 
2011) 
CBT 27 6 (20) COPS, SIPS 
(Miller et al., 
2003a, Miller 
et al., 2003b) 
POPS 
(McGlashan et 
al., 2003) 
1, Toronto, 
(Canada) 
20.8 
(4.5) 
9 (33) SOPS positive, 
10.8 (4.1) 
6, 12, 18  
 Supportive 
therapy 
 
24 6 (20)    21.1 
(3.7) 
6 (25) SOPS positive, 
12.3 (5) 
 
Bechdolf 
2012 
(Bechdolf 
et al., 
2012) 
IPI 
(includes 
CBT) 
63 12 (25) ERIraos 
(Haefner et al., 
2011) 
PANSS5 4, Cologne, 
Borne, 
Dusseldorf, 
Munich, 
(Germany) 
25.2 
(5.4) 
24 (38) PANSS positive, 
9.4 (2.9) 
12, 24 
 Supportive 
counselling 
65 12 (30)    26.8 
(6.2) 
23 (35) PANSS positive, 
9.2 (2.1) 
 
Morrison 
2004 
(Morrison 
et al., 
2004)  
CBT plus 
monitoring 
37 6 (26) PACE (Yung et 
al., 1996a) 
PANSS5 1, Manchester 
(United 
Kingdom) 
20.6 
(4.9) 1 
14 (38) PANSS total, 
61.2 (12.2) 
6, 12, 362 
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       Baseline demographics  
Trial Treatments Number 
randomise
d 
Maximum 
duration of 
treatment, 
months 
(no. 
therapy 
sessions) 
Primary 
criterion used 
to determine 
at-risk mental 
state 
Primary 
criterion used 
to determine 
transition to 
psychosis 
Number of 
centres, 
location 
(country) 
Age, 
mean 
(SD)  
Number 
female 
(%) 
Baseline 
symptom 
severity, 
measure used, 
mean score 
(SD) 
Follow-up 
data 
available 
(months 
after 
baseline) 
 Monitoring 23 n/a     21.5 
(5.2) 1 
4 (17) PANSS total, 
57.5 (7.6) 
 
Morrison 
2012 
(Morrison 
et al., 
2012a) 
CBT plus 
monitoring 
144 6 (26) CAARMS (Yung 
et al., 2005) 
CAARMS (Yung 
et al., 2005) 
5, 
Manchester, 
Birmingham, 
Glasgow, 
Cambridge, 
Norfolk 
(United 
Kingdom) 
20.7 
(4.2) 
55 (38) CAARMS 
severity total, 
38.7 (16.8) 
6, 12, 24 
 Monitoring 144 n/a    20.8 
(4.5) 
53 (37) CAARMS 
severity total, 
38.2 (17.8) 
 
McGorry 
2012 
(McGorry 
et al., 
2012, Yung 
et al., 
2011) 4 
CBT plus 
risperidone 
43 12 (NS)3 CAARMS (Yung 
et al., 2005) 
CAARMS (Yung 
et al., 2005) 
1, Melbourne 
(Australia) 
NS NS BPRS total, 28.1 
(9.2) 
6, 12, 18 
 CBT plus 
placebo 
44 12 (NS)3    NS NS BPRS total, 29.1 
(9.0) 
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       Baseline demographics  
Trial Treatments Number 
randomise
d 
Maximum 
duration of 
treatment, 
months 
(no. 
therapy 
sessions) 
Primary 
criterion used 
to determine 
at-risk mental 
state 
Primary 
criterion used 
to determine 
transition to 
psychosis 
Number of 
centres, 
location 
(country) 
Age, 
mean 
(SD)  
Number 
female 
(%) 
Baseline 
symptom 
severity, 
measure used, 
mean score 
(SD) 
Follow-up 
data 
available 
(months 
after 
baseline) 
 Supportive 
therapy 
plus 
placebo 
28 12 (NS)3    NS NS BPRS total, 26.8 
(9.3) 
 
Van der 
Gaag, 
(Rietdijk et 
al., 2010, 
van der 
Gaag, 
2012, van 
der Gaag 
et al., 
2012) 
CBT plus 
monitoring 
98 6 (26) CAARMS (Yung 
et al., 2005) 
CAARMS (Yung 
et al., 2005) 
2, The Hague, 
Friesland 
(Netherlands) 
22.9 
(5.6) 
49 (50) CAARMS 
positive, 10.2 
(3)  
6, 12, 18 
 Monitoring 103 n/a    22.6 
(5.5) 
53 
(51.5) 
CAARMS 
positive, 10.3 
(2.5) 
 
Not included in meta-analysis 
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       Baseline demographics  
Trial Treatments Number 
randomise
d 
Maximum 
duration of 
treatment, 
months 
(no. 
therapy 
sessions) 
Primary 
criterion used 
to determine 
at-risk mental 
state 
Primary 
criterion used 
to determine 
transition to 
psychosis 
Number of 
centres, 
location 
(country) 
Age, 
mean 
(SD)  
Number 
female 
(%) 
Baseline 
symptom 
severity, 
measure used, 
mean score 
(SD) 
Follow-up 
data 
available 
(months 
after 
baseline) 
Bechdolf, 
ongoing 
(Bechdolf 
et al., 
2011) 
Aripipipraz
ole and CM 
NS (as at 
Nov 2010, 
156 
randomise
d. Target 
N=240) 
12 (20) EPOS 
(Klosterkotter 
et al., 2005) 
SOPS / POPS 
(McGlashan et 
al., 2003) 
9, Cologne, 
Bonn, Aachen, 
Dusseldorf, 
Bochum, 
Hamburg, 
Gottingen, 
Munchen, 
Berlin 
(Germany) 
NS NS SIPS / PANSS 6, 12 
 Placebo 
and CM 
NS (as at 
Nov 2010, 
156 
randomise
d. Target 
N=240) 
12 (20)        
 CBT NS (as at 
Nov 2010, 
156 
randomise
d. Target 
N=240) 
12 (30)        
Stain, 
unpublishe
d 
CBT NS 
(planned 
total N = 
78) 
6 (NS) CAARMS (Yung 
et al., 2005) 
CAARMS (Yung 
et al., 2005) 
2, Newcastle, 
Orange 
(Australia) 
NS NS NS 6, 12 
32 
 
       Baseline demographics  
Trial Treatments Number 
randomise
d 
Maximum 
duration of 
treatment, 
months 
(no. 
therapy 
sessions) 
Primary 
criterion used 
to determine 
at-risk mental 
state 
Primary 
criterion used 
to determine 
transition to 
psychosis 
Number of 
centres, 
location 
(country) 
Age, 
mean 
(SD)  
Number 
female 
(%) 
Baseline 
symptom 
severity, 
measure used, 
mean score 
(SD) 
Follow-up 
data 
available 
(months 
after 
baseline) 
 NDRL NS 
(planned 
total N = 
78) 
6 (NS)        
Note: CBT, Cognitive Behavioural Therapy; IPI, Integrated Psychological Intervention; COPS, Criteria of Prodromal States; SIPS, Structured Interview for 
Prodromal Symptoms; SOPS, Scale of Prodromal Symptoms; POPS, Presence of Psychotic Symptoms; PANSS, Positive and Negative Syndrome Scale; PACE, 
Personal Assessment and Crisis Evaluation; CAARMS, Comprehensive Assessment of At Risk Mental State; BPRS, Brief Psychiatric Rating Scale; EPOS, 
European Prediction of Psychosis study; CM, Clinical Management; NDRL, Non-Directive Reflective Listening; NS, Not Supplied. 1 Median (range); 2 36-month 
data not reported here as attrition >50%; 3 CBT was “offered weekly to fortnightly, depending on clinical need” and supportive therapy was “offered weekly 
to monthly, depending on clinical need” (Yung et al., 2011); 4 Data from an additional non-randomly allocated ‘monitoring’ group, consisting of those who 
declined to enter the formal trial, was also presented but is not included here; 5PANSS transition defined as a score of 4 or more on items measuring 
hallucinations and delusions and / or 5 or more on item measuring conceptual disorganisation, with a frequency of at least several times a week, and 
duration of more than 1 week.  
 
